| 4.22 Data as of May 17 |  +0.01 / +0.24%Today’s Change | 2.22 Today|||52-Week Range 4.40 | +75.83% Year-to-Date |
| Positive Data on Celgene's Apremilast - Analyst Blog May 09 / Zacks.com | VIVUS Reports Wider Loss - Analyst Blog May 09 / Zacks.com |
| ARNA Sheds Light on Belviq Launch - Analyst Blog May 09 / Zacks.com |
| Previous close | 4.21 |
| Today’s open | 4.23 |
| Day’s range | 4.15 - 4.24 |
| Volume | 483,679 |
| Average volume (3 months) | 666,888 |
| Market cap | $349.8M |
| Dividend yield | -- |
| Earnings growth (last year) | -5.77% |
| Earnings growth (this year) | +25.29% |
| Earnings growth (next 5 years) | +36.00% |
| Revenue growth (last year) | -41.95% |
| P/E ratio | NM |
| Price/Sales | 4.59 |
| Price/Book | 16.21 |
| Today’s change | Today’s % change | |
|---|---|---|
| LCILannett Company Inc | +0.16 | +1.32% |
| INSMInsmed Inc | +0.34 | +3.22% |
| GTXIGTX Inc | +0.11 | +1.98% |
| TXMDTherapeuticsMD Inc | -0.19 | -6.42% |
| Next reporting date | August 12, 2013 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $33.8M |
| Annual profit (last year) | -$71.1M |
| Net profit margin | -210.36% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director John W. Varian |
Chief Financial Officer & Vice President Fred Kurland, MBA |
Corporate headquarters Berkeley, California |
.
